Compare Abeona Therapeutics Inc (ABEO) vs Delta Air Lines, Inc. (DAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Delta Air Lines, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while Delta Air Lines, Inc. trades at $86.82 (market cap $58.23B). The key difference: Delta Air Lines, Inc. is far larger — about 156× Abeona Therapeutics Inc's market cap, and Delta Air Lines, Inc. pays a 0.88% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | DAL | |
|---|---|---|
Market Cap | $373.32M | $58.23B |
Sector | Health | Industrials |
52-Week High | $7.23 | $93.66 |
52-Week Low | $4.17 | $50.52 |
Enterprise Value | $228.22M | $73.48B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Delta Air Lines (DAL) trades at $88.63, down 4.44% today, but maintains strong fundamentals with consistent earnings beats and improving cash flow. The stock shows bullish technical signals with moving averages supporting upward momentum, while trading near key support at $88. Analysts remain overwhelmingly positive with 81% buy ratings and a $105.36 consensus target, representing 19% upside potential from current levels.
DAL presents a compelling investment case with attractive valuation multiples (P/E 13.38, P/S 0.92) and robust profitability (ROE 24.99%). However, investors face risks from fuel price volatility, labor cost pressures, and cyclical industry exposure. The upcoming Q2 earnings report on July 10 will be critical for validating current momentum and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →
